Comparative Pharmacology
Head-to-head clinical analysis: OGEN 625 versus OGEN 2 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OGEN 625 versus OGEN 2 5.
OGEN .625 vs OGEN 2.5
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Estrogen replacement therapy; estrogen binds to estrogen receptors, which then translocate to the nucleus and modulate gene transcription, leading to effects such as proliferation of the endometrium and regulation of gonadotropin secretion.
Estrogen replacement therapy; binds to estrogen receptors, leading to activation of estrogen-responsive genes and physiological effects mimicking endogenous estrogens.
Treatment of moderate to severe vasomotor symptoms due to menopauseTreatment of vulvar and vaginal atrophy due to menopausePrevention of postmenopausal osteoporosis
Moderate to severe vasomotor symptoms associated with menopauseVulvar and vaginal atrophyHypoestrogenism due to hypogonadism, castration, or primary ovarian failurePrevention of postmenopausal osteoporosis
0.625 mg orally once daily
0.625 mg orally once daily (estropipate 0.75 mg equivalent), cyclic or continuous.
None Documented
None Documented
Estrone: 10-24 hours; equilin: 12-18 hours; terminal half-life supports once-daily dosing.
10-24 hours; terminal half-life may be prolonged in hepatic impairment.
Primarily metabolized in the liver via CYP3A4; undergoes first-pass metabolism including sulfation and glucuronidation. Estropipate is hydrolyzed to estradiol and then metabolized.
Hepatic metabolism via CYP3A4 and other cytochrome P450 enzymes; undergoes enterohepatic recirculation.
Renal (primarily as glucuronide and sulfate conjugates, ~50-80% of a dose), fecal (~10-20%), with enterohepatic recirculation.
Primarily renal as sulfate and glucuronide conjugates; less than 10% excreted unchanged.
~50-80% bound to sex hormone-binding globulin (SHBG) and albumin.
50-60% bound to albumin; no specific binding protein.
Estrone: ~1-2 L/kg; indicates extensive tissue distribution.
12-86 L/kg; widely distributed due to lipophilicity.
Oral: ~30-50% due to first-pass metabolism; micronized formulation enhances absorption.
30-50% after oral administration due to first-pass metabolism.
No dose adjustment required for GFR ≥30 mL/min; insufficient data for GFR <30 mL/min, use with caution
Not studied; avoid in severe renal impairment (CrCl <30 mL/min) due to decreased clearance.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated
Child-Pugh A: no adjustment; B/C: contraindicated due to impaired metabolism.
Not indicated for use in pediatric patients
Not indicated for pediatric use; safety and efficacy not established.
Use lowest effective dose; monitor for thromboembolic events and malignant neoplasms; no specific dose adjustment recommended
Use lowest effective dose for shortest duration; consider increased risk of thromboembolic events and dementia.
Estrogens increase the risk of endometrial carcinoma in postmenopausal women. Also, estrogens should not be used to prevent cardiovascular disease or dementia. Increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis have been reported with estrogen-alone therapy.
Estrogens increase the risk of endometrial cancer in postmenopausal women. Use unopposed estrogens only in women with a hysterectomy. Estrogens with or without progestins should not be used for the prevention of cardiovascular disease or dementia. The Women's Health Initiative (WHI) studies reported increased risks of stroke, deep vein thrombosis, pulmonary embolism, and myocardial infarction in postmenopausal women (50-79 years) receiving conjugated equine estrogens alone or with medroxyprogesterone acetate.
Increased risk of endometrial cancer; cardiovascular disorders (MI, stroke, VTE); probable dementia; breast cancer; gallbladder disease; hypercalcemia; fluid retention; visual abnormalities; hereditary angioedema; exacerbation of asthma, diabetes, epilepsy, migraine, porphyria, SLE, and hepatic hemangiomas; hypothyroidism; elevated triglycerides; and hypersensitivity reactions.
Increased risk of endometrial cancer, cardiovascular disorders, stroke, thromboembolism, dementia, breast cancer (with combined therapy), gallbladder disease, hypercalcemia, visual abnormalities, and exacerbation of endometriosis. Use lowest effective dose for shortest duration.
Undiagnosed abnormal genital bleeding; known, suspected, or history of breast cancer; known or suspected estrogen-dependent neoplasia; active or past history of venous thromboembolism; active or recent arterial thromboembolic disease (e.g., stroke, MI); liver dysfunction or disease; known hypersensitivity to estrogens; known protein C, protein S, or antithrombin deficiency; and pregnancy.
Undiagnosed abnormal genital bleeding; known, suspected, or history of breast cancer; known or suspected estrogen-dependent neoplasia; active or past history of thromboembolic disorders; active or recent arterial thromboembolic disease; known thrombophilic disorders; hepatic impairment or disease; known or suspected pregnancy; hypersensitivity to any ingredient.
Data Pending Review
Data Pending Review
Grapefruit juice may increase estrogen levels; avoid large quantities. No other significant food interactions.
Grapefruit juice may increase estrogen levels; avoid excessive intake. No significant food restrictions otherwise.
First trimester: Estrogens are associated with a potential risk of fetal genital tract abnormalities, including congenital anomalies such as hypospadias and vaginal adenosis. Use is contraindicated in pregnancy. Second and third trimesters: Exposure may increase risk of fetal urogenital tract abnormalities, and estrogens have been linked to an elevated risk of vaginal clear cell adenocarcinoma in female offspring. Overall, use is contraindicated throughout pregnancy due to known fetal risks.
FDA Pregnancy Category X. Estrogens are contraindicated in pregnancy due to increased risk of fetal harm. First trimester: Associations with congenital anomalies (e.g., cardiovascular defects, limb reduction defects). Second and third trimesters: Potential for urogenital tract abnormalities, delayed development, and increased risk of vaginal adenosis and clear-cell carcinoma in female offspring. Use during pregnancy is not indicated.
Estropipate (ogen) is excreted into human breast milk. The milk-to-plasma ratio (M/P ratio) is not established in published literature. Exogenous estrogens may reduce milk production and quality, particularly in early postpartum. Use during breastfeeding is generally not recommended due to potential adverse effects on the infant, including jaundice and long-term effects on reproductive development. Alternative therapies should be considered.
Estropipate is excreted in human milk in low amounts (M/P ratio not established). Case reports suggest minimal transfer. However, estrogens may suppress lactation and affect milk composition. Use during breastfeeding is generally not recommended, especially in the immediate postpartum period due to potential effects on milk production. Discuss with patient individual risk-benefit.
Estropipate is contraindicated in pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased volume of distribution, altered hepatic metabolism) are not relevant due to absolute contraindication. No dose adjustments are applicable as the drug should not be used.
Estropipate is contraindicated in pregnancy; no dose adjustments are applicable. The drug should not be used during pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased clearance, volume of distribution) are not relevant due to contraindication.
Category C
Category C
OGEN 0.625 mg (estropipate) is a conjugated estrogen tablet for hormone therapy. It may increase risk of endometrial cancer; use with progestin in women with intact uterus. Monitor for thromboembolic events. Not for prevention of cardiovascular disease or dementia. Avoid in pregnancy.
OGEN 2.5 (estropipate) is an estrogen replacement therapy. Monitor endometrial thickness with ultrasound if prolonged use. Avoid in patients with estrogen-dependent neoplasia. Use lowest effective dose for shortest duration.
Take exactly as prescribed; do not skip doses or stop without consulting your doctor.Report any unusual vaginal bleeding, chest pain, shortness of breath, or vision changes immediately.Avoid smoking as it increases risk of blood clots.Inform all healthcare providers that you are taking estrogen.Regular breast exams and mammograms are recommended.
Take exactly as prescribed, usually once daily.Report any unusual vaginal bleeding, breast lumps, or leg swelling.Do not smoke while on this medication; increased risk of blood clots.Attend regular gynecologic exams including mammograms and pelvic exams.Take with food if stomach upset occurs.